New Crown vaccination is not recommended for people undergoing dual-targeted therapy, as it may cause an allergic reaction or cause a diminished effect of the targeted therapy. Dual-targeted therapy mainly refers to the application of two targeted drugs, trastuzumab and patuzumab, for anti-tumor treatment. Through the combined use of two targeted drugs to effectively control the proliferation and metastasis of cancer cells, it can enhance the effect of anti-tumor therapy and effectively promote the cure of tumors. However, patients may experience different degrees of immune function impairment or immunity decline during dual-targeted therapy. New Crown vaccine will stimulate the body to experience different degrees of side effects during vaccination, which may manifest as fever, local pain, redness, swelling, etc., and may also manifest as immune stress reaction. If dual-targeted therapy patients receive the new crown vaccination, may be due to their own immunity damage and trigger more serious vaccine side effects, but will cause health damage, so it is not recommended to vaccination. Dual-targeted therapy patients should consult their doctor for advice on whether they can undergo various types of vaccinations.